Table 1.

Patient characteristics

Dutch Biologic Monitor
n=404
DREAM-RA
n=341
Age, median (IQR), years57.0 (49.0-65.0)56.0 (46.0-65.0)
Female, n (%)279 (73.5)240 (70.4)
Indication for bDMARD therapy, n (%)
Rheumatoid arthritis299 (74.0)381 (89.4)
Psoriatic arthritis105 (26.0)45 (10.6)
bDMARD use, n (%)
Etanercept164 (40.6)152 (34.9)
Adalimumab134 (33.2)119 (44.6)
Tocilizumab32 (7.9)48 (14.1)
Other100 (24.8)107 (31.4)